Politico reports that Republicans have joined Democrats in blaming large pharmacy groups, including CVS, for high drug prices. The article points to rising bipartisan political pressure on pharmacy benefit managers, which play a major role in the US drug supply chain.

This matters for senior executives in healthcare and pharma, as it signals a shift in the political environment. Bipartisan scrutiny may lead to tougher regulation or changes in how pharmacy benefit managers operate. Leaders should monitor for possible policy changes affecting pricing, contracts and market access.

A federal judge has ruled that regulators exceeded their authority by restricting the exceptions to Medicaid work requirements for individuals with medical conditions, according to STAT. The decision challenges recent efforts to redefine which patients qualify as too frail for mandated work activities under Medicaid.

This ruling matters for health insurers and healthcare providers who must comply with federal Medicaid policy. It may limit future regulatory changes to eligibility criteria and affect how states design their Medicaid programmes. Leaders should monitor for further legal developments that could alter compliance obligations.

The US Justice Department is reviewing Nvidia’s $12.9 billion acquisition of Hugging Face, according to Reuters. Officials are asking whether the deal would give Nvidia control over a critical distribution point for AI models and if it could use this position to disadvantage competitors. This inquiry is part of a broader, ongoing investigation into Nvidia’s business practices, which includes its investments, chip sales, and previous deals.

Hugging Face is a leading platform for sharing open AI models and data. Nvidia agreed to acquire the company in September, stating it would keep the platform open. The deal is expected to close in the first half of 2027. The DOJ has declined to comment on the specifics but said it will continue to focus on the development of advanced AI, which the White House calls “Super Intelligence.”

Nvidia is also under antitrust scrutiny in France and has faced questions over its $20 billion Groq deal, which involved licensing technology and hiring executives rather than a full acquisition. The company is in talks for further investments in Reflection AI, another open model developer.

Regulatory attention on Nvidia’s expansion into software and AI models could affect how banks, insurers, and healthcare firms access and deploy AI tools. Executives should monitor the outcome for potential changes in competition and technology procurement.

Equifax has agreed to pay $100 million to settle a class action lawsuit alleging it miscalculated credit scores for around 4 million Americans, according to Fast Company. The suit claimed a coding error led to inaccurate credit report information over a three-week period in 2022, affecting those who applied for mortgages, auto loans, or credit cards.

The settlement comes with no admission of fault from Equifax, which denied violating the Fair Credit Reporting Act. The company and plaintiffs agreed to settle to avoid the uncertainty and cost of further litigation. For banks and insurers, the case draws attention to the risks of data errors in credit reporting and the potential for regulatory or legal action.

Emerging state and federal laws are raising new concerns about algorithmic pricing, according to Simpson Thacher & Bartlett LLP partner Laura Brett, as reported by Marketing Dive. The article notes that legal scrutiny of these pricing strategies is increasing, with marketers facing evolving risks.

This matters for regulated industries such as financial services and pharma, where compliance failures can mean fines or reputational damage. Marketers should review their pricing models and stay alert to changes in regulation and enforcement.

STAT reports that Vertex’s kidney disease drug is being closely examined for infection risk as the FDA prepares to make an approval decision on 30 November. The scrutiny reflects regulatory attention to safety concerns in new therapies, especially for high-risk patient groups.

For pharma executives, this signals the importance of addressing safety data in regulatory submissions and market planning. The FDA’s approach may influence how similar drugs are evaluated and could shape future approval timelines and requirements.

A proposed Treasury rule has caused disagreement in the biopharma industry, according to STAT. The dispute centres on an exemption for a common type of transaction involving China, which some firms argue could affect their business models and partnerships.

This matters for pharma and biotech executives, as regulatory changes may alter the risk profile of cross-border deals and impact drug development timelines. Firms should review their exposure to affected deal types and prepare for possible adjustments if the rule is finalised.

A Trump administration rule will force pharmacy benefit managers to disclose fees and compensation details currently kept private, according to STAT. The move targets the opaque financial arrangements that have long shaped drug pricing in the US.

This matters for health insurers and pharmaceutical firms, as greater transparency could change how contracts are structured and how much is paid for medicines. It may also prompt further regulatory attention to pricing practices in the sector.

Binance, the world's largest cryptocurrency exchange, has confirmed a security incident after users reported funds being drained from its wallets, TechCrunch reports. Binance has temporarily suspended withdrawals across several networks as a precaution. The company says user funds are safe and its security teams are investigating, but has not confirmed the full scale of the breach.

Crypto analysts estimate that at least $2 billion, and possibly up to $5.7 billion, may have been stolen from Binance's hot wallets. Circle and Tether, two major stablecoin firms, have frozen over $2 billion in assets linked to the breach. Binance has not identified the attackers or confirmed whether the theft is ongoing.

If the losses are confirmed, this would be among the largest crypto thefts recorded. The breach follows a recent $1.4 billion hack at Bybit in 2025. The incident highlights the persistent risks for financial firms and fintechs that rely on crypto exchanges for custody and settlement.

Executives at regulated firms should review their exposure to crypto infrastructure and ensure their own security and contingency plans are up to date. Watch for further updates from Binance and potential regulatory responses.

A White House-backed plan to relax FDA oversight on certain peptide drugs was opposed by most FDA scientific staff, who had little input in drafting the policy, according to Fast Company. The proposal, driven by Health Secretary Robert F. Kennedy Jr., would allow specialty pharmacies to sell some injectable peptides without the usual FDA review. The policy recently underwent regulatory review at the White House, which is typically the last step before publication.

This internal resistance signals regulatory uncertainty for pharma and healthcare leaders, as FDA staff warned the move could undermine the agency’s mission to keep unproven drugs off the market. Senior executives should monitor how these divisions affect enforcement and compliance expectations.